Clinical Trial Update: Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated tolerability and efficacy of AM and PM once-daily extended-release guanfacine hydrochloride for children aged 6-12 with ADHD; study co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• guanfacine hydrochloride extended-release (AM/PM once-daily) (guanfacine hydrochloride extended-release)

Snippet

Sponsor: Shire | Conditions: Attention-Deficit/Hyperactivity Disorder | Phase 3 | Status: COMPLETED | Results posted: 2011-10-26